SRT Sartorius AG

Sartorius appoints Gerry MacKay as Executive Vice President of Marketing, Sales and Services for its Laboratory Division

Sartorius, a leading international pharmaceutical and laboratory equipment provider, today announces the appointment of Gerry MacKay as Executive Vice President of Marketing, Sales and Services for its Lab Products & Services Division (LPS) with immediate effect. MacKay will report to CEO Dr. Joachim Kreuzburg, and be a member of the Group Executive Committee, the key management body of the Sartorius Group.

Gerry MacKay, who brings in a broad international background in the biopharma business, joined Sartorius in 2015 through the acquisition of BioOutsource, a contract testing services company, where he had served as CEO. Prior to his tenure with BioOutsource, he held senior level positions with Entegris, Mykrolis and Millipore.

“We are very pleased that Gerry has accepted this new challenging position at Sartorius. His considerable experience in the global biopharma market will be instrumental to strengthen the momentum on our LPS division´s new strategic direction towards Biopharma and respective applications and technologies”, said Sartorius CEO Joachim Kreuzburg.

MacKay assumes the role of his predecessor, Michael Melingo.

A Profile of Sartorius

The Sartorius Group (FWB:SRT) is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. 7,000 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe.

EN
09/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sartorius AG

Sartorius: 1 director

A director at Sartorius bought 400 shares at 173.350EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

Thomas J. Schiessle
  • Thomas J. Schiessle

CEO verlängert nicht über Nov. 2025 hinaus - Q1/24 dokumentierte opera...

Nach knapp 20 Jahren als hat CEO Dr. Joachim Kreuzburg angekündigt – aus Gründen der persönlichen Lebensplanung - keine nochmalige Vertrags­verlängerung - über den 30.11.25 hinaus – anzustreben; er strebe ferner keine operative Position in einem anderen Unternehmen an. Die Ankeraktionäre werden nun wichtig: Seit in 2023 ist Bio-Rad Laboratories Inc. Aktionär (derzeit Anteil an  Ord. 28%; Pref: 38%). Durch Lothar Kappich (SRT-AR-Vorsitz) wird die Horst Sartorius Erbengemeinschaft in Höhe von 50,0...

Thomas J. Schiessle
  • Thomas J. Schiessle

CEO will not extend beyond Nov. 2025 - Q1/24 documented operational tu...

After almost 20 years as CEO, Dr Joachim Kreuzburg has announced - for reasons of personal life planning - that he will not seek a further contract extension beyond 30.11.2025; furthermore, he will not seek an operational position in another company. The anchor shareholders are now becoming important: Bio-Rad Laboratories Inc. has been a shareholder since 2023 (current share in Ord. 28%; Pref: 38%). Lothar Kappich (SRT-SB-Chairman) represents the Horst Sartorius community of heirs in the amount ...

 PRESS RELEASE

EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuz...

EQS-News: SARTORIUS AG / Key word(s): Personnel Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret (news with additional features) 02.07.2024 / 10:53 CET/CEST The issuer is solely responsible for the content of this announcement.   Göttingen, July 2, 2024 Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret The long-standing CEO of Sartorius AG, Dr. Joachim Kreuzburg, has informed the ...

 PRESS RELEASE

EQS-News: Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahr...

EQS-News: SARTORIUS AG / Schlagwort(e): Personalie Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern (News mit Zusatzmaterial) 02.07.2024 / 10:53 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Göttingen, 2. Juli 2024 Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern Der langjährige Vorstandsvorsitzende der Sartorius AG, Dr. Joachim ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch